Natixis Advisors LLC Raises Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Natixis Advisors LLC grew its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 86.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 121,560 shares of the biopharmaceutical company's stock after buying an additional 56,461 shares during the quarter. Natixis Advisors LLC owned 0.10% of Halozyme Therapeutics worth $6,958,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently bought and sold shares of the company. GAMMA Investing LLC increased its stake in Halozyme Therapeutics by 96.6% during the second quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 254 shares during the period. International Assets Investment Management LLC purchased a new stake in Halozyme Therapeutics during the 2nd quarter worth approximately $33,000. Skandinaviska Enskilda Banken AB publ acquired a new stake in Halozyme Therapeutics during the 2nd quarter worth approximately $49,000. Toth Financial Advisory Corp purchased a new position in Halozyme Therapeutics in the 3rd quarter valued at approximately $57,000. Finally, FSC Wealth Advisors LLC acquired a new position in shares of Halozyme Therapeutics in the third quarter worth $65,000. Institutional investors and hedge funds own 97.79% of the company's stock.

Insider Buying and Selling at Halozyme Therapeutics

In related news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $62.03, for a total value of $620,300.00. Following the transaction, the senior vice president now directly owns 173,756 shares in the company, valued at $10,778,084.68. This trade represents a 5.44 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Over the last three months, insiders have sold 60,000 shares of company stock worth $3,425,000. 2.40% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on HALO. HC Wainwright reiterated a "buy" rating and issued a $68.00 target price on shares of Halozyme Therapeutics in a report on Wednesday. Piper Sandler upped their target price on shares of Halozyme Therapeutics from $51.00 to $52.00 and gave the stock a "neutral" rating in a research note on Monday, November 4th. JMP Securities boosted their price target on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a "market outperform" rating in a report on Friday, November 1st. JPMorgan Chase & Co. cut shares of Halozyme Therapeutics from an "overweight" rating to a "neutral" rating and lifted their price objective for the stock from $52.00 to $57.00 in a research report on Thursday, September 19th. Finally, Morgan Stanley increased their target price on Halozyme Therapeutics from $59.00 to $64.00 and gave the company an "overweight" rating in a report on Wednesday, August 7th. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, Halozyme Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $61.11.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ HALO traded up $3.30 during trading hours on Friday, reaching $49.00. The stock had a trading volume of 4,543,771 shares, compared to its average volume of 1,368,893. The firm has a market cap of $6.23 billion, a price-to-earnings ratio of 16.18, a PEG ratio of 0.41 and a beta of 1.29. Halozyme Therapeutics, Inc. has a fifty-two week low of $33.15 and a fifty-two week high of $65.53. The firm has a 50-day moving average of $54.85 and a 200-day moving average of $53.42. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.